Based on this, we conducted Co-IP assays using A549 lung cancer cells, which revealed that SMARCB1 interacts with MEOX2, GLI-1, and BRD9, with a potential weak interaction with CBP and EZH2. Here, SMARCB1 is linked to lung carcinoma.